1. Top of page
  2. Abstract
  3. Patients and Methods
  4. Results
  5. Discussion
  6. References

Hepatocellular carcinoma (HCC) frequently recurs after surgical resection. This population-based research aimed to investigate the association between postoperative antiviral treatment and risk of recurrent HCC in patients with hepatitis C virus (HCV) infection. By analyzing the Taiwan National Health Insurance Research Database, we initially screened a total of 100,938 patients diagnosed with HCC for the first time between October 2003 and December 2010. Among 2,237 antiviral-naïve HCV-infected patients with curatively resected HCC, there were 213 patients receiving antiviral treatment with pegylated interferon plus ribavirin for 16 weeks or more after surgery (treated cohort). These treated patients were matched 1:4 with 852 controls who were never treated for HCV infection (untreated cohort) by age, gender, cirrhosis, and the elapsed time between surgery and antiviral therapy. Cumulative incidences of and hazard ratios for recurrent HCC were calculated after adjusting for competing mortality. The recurrence rate of HCC was significantly lower in the treated than untreated cohort, with 52.1% (95% confidence interval [CI], 42.0-62.2%) and 63.9% (95% CI, 58.9-68.8%) after 5 years of follow-up, respectively (P = 0.001). The number needed to treat for one fewer recurrent HCC at 5 years was 8. The association between postoperative antiviral treatment and risk of recurrent HCC was independent of adjustment for multiple covariates, with an adjusted hazard ratio of 0.64 (95% CI, 0.50-0.83). Stratified analyses revealed that the attenuation in recurrence risk was greater in patients younger than 60 years and those without cirrhosis or diabetes. Conclusion: Postoperative pegylated interferon plus ribavirin is associated with reduced recurrence of HCC in patients with HCV infection. Age, liver cirrhosis, and diabetes mellitus appear to modify this association. (HEPATOLOGY 2013)

Hepatocellular carcinoma (HCC) is the third most lethal cancer worldwide, causing ∼600,000 deaths every year. The incidence is highest in Eastern Asia and sub-Saharan Africa, but appears to be on the rise in North America.1, 2 Almost all HCCs occur in the background of chronic liver diseases that include viral hepatitis, alcoholic liver disease, and steatohepatitis.3 Chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV) accounts for most HCCs; chronic hepatitis C (CHC) is the leading etiology in countries where the prevalence of HBV infection is low.4, 5

Surgical resection is potentially curative for HCC and has been recommended as the treatment of choice if the hepatic reserve permits complete resection.6, 7 Nevertheless, recurrence is very common and strikes 50%-60% of patients 3 years after operation.8, 9 In addition to insidious intrahepatic spreading prior to surgery, a large proportion of recurrent HCCs originate from de novo tumor clones distinct to the resected ones.10, 11 This may result from the underlying liver disease that continuously promotes hepatocellular carcinogenesis despite removal of the primary tumor. There remains a huge unmet need for effective therapy to prevent postoperative recurrence.6, 7

Antiviral therapy may reduce the risk of HCC in patients with chronic viral hepatitis through elimination of viral oncoprotein, resolution of hepatic inflammation, and amelioration of the carcinogenic microenvironment.12-14 A growing body of evidence has indicated that interferon-based antiviral regimen may decrease development of HCC in CHC patients, particularly in those achieving sustained virological response.15, 16 Nonetheless, viral clearance cannot prevent all HCCs, especially in those of old age or with severe liver fibrosis,17 indicating that antiviral therapy may be too late to halt hepatocarcinogenesis in patients with advanced disease. The recurrence rate after HCC resection remained unknown in CHC patients receiving postoperative pegylated interferon (peg-interferon) plus ribavirin, the standard anti-HCV regimen for a decade.18 Moreover, it has not been clarified whether this antiviral regimen administered postoperatively was associated with fewer HCC recurrences. Therefore, we aimed in this population-based study to determine the recurrence rate of surgically resected HCC after postoperative administration of peg-interferon plus ribavirin, and to elucidate whether this antiviral therapy was associated with reduced recurrence of HCC in CHC patients.

Patients and Methods

  1. Top of page
  2. Abstract
  3. Patients and Methods
  4. Results
  5. Discussion
  6. References

Study Design and Patient Population.

This open-cohort research utilized population-based data from the Taiwan National Health Insurance Research Database (NHIRD). Since National Health Insurance is a compulsory universal program for all residents in Taiwan, NHIRD is a comprehensive healthcare database that nearly covers the entire 23.7 million population of this country. Details regarding NHIRD have been reported in our previous investigations.19-21 The present study was approved by the Research Ethics Committee of the National Health Research Institutes, Taiwan (EC1010303-E).

We first screened all patients who had a first-time diagnosis of HCC from October 1, 2003, to December 31, 2010, and then identified the study population as those with CHC who underwent curative surgery. This research defined disease status principally on the basis of admission diagnoses, which were coded according to the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM). Apart from the specific ICD-9-CM code (155.0), the diagnosis of HCC had to be certified in the Registry for Catastrophic Illness Patient Database (RCIPD), a subpart of NHIRD. Given that all enrolled patients had their HCC resected, histopathological confirmation was required for registry in the RCIPD. All enrolled patients received liver resection as the sole HCC treatment. Those who underwent liver transplantation, local ablation (ethanol injection, radiofrequency ablation, or microwave coagulation), or transarterial chemoembolization before or during the index admission were excluded.

Patients with metastasis or any other malignant disease were excluded. We enrolled exclusively patients coded with CHC at admission (ICD-9-CM codes: 070.41, 070.44, 070.51, 070.54, V02.62) to ascertain validity of the diagnosis. Those with HBV infection or other viral hepatitis were excluded (ICD-9-CM codes: 070.2, 070.3, V02.61, V02.69).

Antiviral Therapy and Definition of Study Cohorts.

The antiviral regimen consisted of peg-interferon alpha (either 2a or 2b) plus ribavirin, which has been reimbursed for HCV infection in Taiwan since October 1, 2003. Generally, treatment was initiated at 180 μg per week irrespective of body weight for peg-interferon alpha 2a, 1.5 μg/kg per week for 2b, and 800 to 1,200 mg per day for ribavirin, but it was individualized at the treating physician's discretion and frequently adjusted along the course. The reimbursed duration ranged from 16 weeks to 48 weeks, depending on the date of administration, viral genotype, serum viral load, on-treatment virological response, and patient tolerability.18

The treated cohort comprised antiviral-naïve patients who received peg-interferon and ribavirin for a minimum of 16 weeks after surgery. Each treated patient was matched in age, gender, and cirrhosis with four untreated counterparts randomly selected from those who never used interferon or ribavirin. Furthermore, the untreated controls were deliberately matched for the time period between surgery and administration of antiviral therapy in treated patients in order to eliminate the immortal time bias.22, 23

Postoperative Follow-up and Definition of HCC Recurrence.

The treated and untreated cohorts were followed up after initiation of antiviral regimen and matched postoperative duration, respectively, until recurrence of HCC, death, or December 31, 2010, whichever occurred first. Recurrence of HCC was defined as repeated cancer treatment for HCC during the follow-up period. Treatment modalities for HCC recurrence included liver transplantation, surgical resection, focal ablation, transarterial chemoembolization, radiotherapy, and chemotherapy. HCC that recurred within 3 months of the index surgery was not included because it might arise from incomplete primary resection.

Assessment of and Adjustment for Confounding Factors.

All comorbidities listed in the Charlson's index were considered as important covariates that might confound outcomes.24 The age-unadjusted Charlson scores were computed for both the treated and untreated cohorts. Certain medications including statin, nonsteroidal antiinflammatory drug (NSAID), aspirin, and metformin were also assessed as potential confounders because they might modify the risk of cancer.19-21 Users of these drugs were defined as those who took them on a regular basis with frequency of more than one tablet per month during the study period. The extent of hepatic surgery, namely, major (at least three segments of hepatic parenchyma) or minor resection (two or fewer segments of liver), was also analyzed.

Data Analysis and Statistical Test.

The primary and secondary outcomes were HCC recurrence and mortality, respectively. Death occurring prior to HCC recurrence, which could lead to informative censoring, was regarded as a competing risk event in estimating the incidence of recurrent HCC. The number needed to treat (NNT) represented the number of patients needed to be treated in association with one fewer recurrent HCC or death. NNT was calculated by the inverse of the absolute risk reduction. The modified Kaplan-Meier method and Gray's method were used to calculate and to compare the cumulative incidences in data with competing risks.25 After confirming the assumption of proportional hazards by plotting the graph of the survival function versus the survival time and the graph of the log (-log(survival)) versus the log of survival time, we applied the modified multivariate-adjusted Cox proportional hazard model in the presence of competing risks to examine the independent risk factors for HCC recurrence.26 The influence of antiviral therapy on HCC recurrence was further explored in stratified analyses according to age, gender, cirrhosis, comorbidity, medications, and extent of resection. All data were managed with SAS software 9.2 v. (SAS Institute, Cary, NC). The cumulative incidence and hazard ratio (HR) in the competing risk analysis were calculated using the R software with the “cmprsk_2.1-4” package (by Gray;∼gray/). Calculated results were expressed with the estimated numbers alongside their 95% confidence intervals (CIs). All statistical tests were two-sided with significance set at P < 0.05.


  1. Top of page
  2. Abstract
  3. Patients and Methods
  4. Results
  5. Discussion
  6. References

Baseline Characteristics of the Study Population.

We screened a total of 100,938 patients diagnosed with HCC for the first time during the study period and finally identified 2,237 CHC patients who underwent curative resection for HCC (Fig. 1). Among the 239 patients who ever received peg-interferon plus ribavirin after surgery, 213 patients (89.1%) were treated for a minimum of 16 weeks and formed the treated cohort, whose mean (± standard deviation) duration of antiviral regimen was 25.99 ± 8.13 weeks and that of follow-up was 2.01 ± 1.67 years. The matched controls accordingly comprised 852 untreated patients randomly selected from those not receiving antiviral therapy. The untreated cohort was followed up for 1.51 ± 1.28 years. These two cohorts were generally comparable in baseline characteristics (Table 1).

thumbnail image

Figure 1. Flow diagram of identification and enrollment of the study subjects. CHC, chronic hepatitis C; HCC, hepatocellular carcinoma.

Download figure to PowerPoint

Table 1. Baseline Characteristics of the Study Cohorts
CharacteristicsUntreated Cohort (n = 852)Treated Cohort (n = 213)P value
  1. Data are expressed as median (interquartile range) or number (percentage). NSAID, nonsteroidal antiinflammatory drug.

Age, year63.4 (58.5-68.6)62.1 (56.7-68.5)0.060
  20-29 years, n (%)1 (0.1)0 (0.0) 
  30-39 years, n (%)1 (0.1)0 (0.0) 
  40-49 years, n (%)30 (3.5)14 (6.6) 
  50-59 years, n (%)230 (27.0)71 (33.3) 
  60-69 years, n (%)440 (51.6)92 (43.2) 
  ≧70 years, n (%)150 (17.6)36 (16.9) 
Male gender, n (%)564 (66.2)141 (66.2)1.000
Extent of surgery  0.155
 Major resection184 (21.6)36 (16.9) 
 Minor resection668 (78.4)177 (83.1) 
Major coexisting diseases, n (%)   
  Liver cirrhosis328 (38.5)82 (38.5)1.000
  Diabetes mellitus225 (26.4)44 (20.7)0.094
  Coronary artery disease61 (7.2)19 (8.9)0.384
  Cerebral vascular accident44 (5.2)10 (4.7)0.863
  Chronic obstructive   lung disease61 (7.2)13 (6.1)0.654
  Renal failure38 (4.5)5 (2.3)0.241
  Hypertension350 (41.1)56 (26.3)<0.001
  Hyperlipidemia8 (0.9)2 (0.9)1.000
  Peptic ulcer disease156 (18.3)37 (17.4)0.842
Charlson scores3 (2-4)3 (2-4)0.110
Drugs use   
  Statin40 (4.7)12 (5.6)0.594
  NSAIDs or aspirin561 (65.8)148 (69.5)0.331
  Metformin181 (21.2)45 (21.1)1.000

HCC Recurrence and Mortality Between the Study Cohorts.

HCC recurred cumulatively in 16.2% (95% CI, 10.9-21.4%), 41.8% (95% CI, 33.2-50.4%), and 52.1% (95% CI, 42.0-62.2%) of the treated cohort after 1, 3, and 5 years of follow-up, respectively (Fig. 2). The corresponding 1-, 3-, and 5-year cumulative incidences in the untreated cohort were 24.5% (95% CI, 21.4-27.5%), 54.3% (95% CI, 50.0-58.6%), and 63.9% (95% CI, 58.9-68.8%), respectively. Therefore, patients receiving a postoperative anti-HCV regimen had a significantly lower recurrence rate (P = 0.001). The unadjusted NNT associated with one fewer HCC recurrences after 1, 3, and 5 years were 12, 8, and 8, respectively (Table 2).

thumbnail image

Figure 2. Recurrence of surgically resected hepatocellular carcinoma in patients treated with postoperative antiviral therapy (treated cohort, blue line) and matched controls without antiviral treatment (untreated cohort, red line); death prior to recurrence is adjusted as a competing cause of risk.

Download figure to PowerPoint

Table 2. Cumulative Incidences of Recurrent HCC and Overall Mortality Between Chronic Hepatitis C Patients With and Those Without Postoperative Antiviral Treatment
 Treated, (95% CI)Untreated, (95% CI)P value*NNT
  • *

    Two sample proportion test.

  • Abbreviations: HCC, hepatocellular carcinoma; CI, confidence interval; NNT, number needed to treat.

HCC recurrence    
 At 1 year16.2%, (10.9-21.4%)24.5%, (21.4-27.5%)0.00512
 At 3 years41.8%, (33.2-50.4%)54.3%, (50.0-58.6%)0.0018
 At 5 years52.1%, (42.0-62.2%)63.9%, (58.9-68.8%)0.0028
 At 1 year2.8%, (0.4-5.2%)6.9%, (5.1-8.7%)0.00424
 At 3 years10.8%, (4.9-16.6%)24.8%, (20.9-28.6%)<0.0017
 At 5 years15.4%, (7.7-23.1%)47.0%, (40.7-53.2%)<0.0013

The treated cohort also had a significantly lower mortality rate as compared with the untreated counterpart (P < 0.001). The 1-, 3-, and 5-year cumulative incidences of mortality were 2.8% (95% CI, 0.4-5.2%), 10.8% (95% CI, 4.9-16.6%), and 15.4% (95% CI, 7.7-23.1%) in the treated patients, and 6.9% (95% CI, 5.1-8.7%), 24.8 (95% CI, 20.9-28.6%), and 47.0% (95% CI, 40.7-53.2%) in the untreated controls (Fig. 3). The unadjusted NNT associated with one less mortality at 1, 3, and 5 years after antiviral treatment were 24, 7, and 3, respectively (Table 2).

thumbnail image

Figure 3. The mortality rates between the treated (blue line) and untreated cohorts (red line).

Download figure to PowerPoint

Multivariate-Adjusted Association of Antiviral Therapy with HCC Recurrence.

The modified Cox proportional hazard model demonstrated that postoperative antiviral therapy was independently associated with a 36% reduction in hazard of HCC recurrence (adjusted HR, 0.64; 95% CI, 0.50-0.83; P = 0.001) (Table 3). In addition, major surgical resection as compared with a minor one (adjusted HR, 0.76; 95% CI, 0.59-0.97; P = 0.027) and regular NSAID or aspirin use (adjusted HR, 0.80; 95% CI, 0.66-0.97; P = 0.026) were also linked to reduction of recurrent HCC.

Table 3. Results of Multivariate-Adjusted Cox Proportional Hazard Model for Recurrence of Hepatocellular Carcinoma
 Adjusted Hazard Ratio95% Confidence IntervalP
Antiviral treatment0.640.50-0.830.001
Age, per year0.990.98-1.000.073
Male gender1.221.00-1.490.056
Major resection0.760.59-0.970.027
Diabetes mellitus1.010.77-1.330.950
Statin use0.930.60-1.450.750
NSAID or aspirin0.800.66-0.970.026
Metformin use0.840.63-1.130.250

Stratified Analyses for Recurrent HCC in Association with Antiviral Therapy.

The association between postoperative antiviral therapy and reduced HCC recurrence was generally consistent across different patient subgroups, since the estimated HRs favored antiviral treatment in all strata (Fig. 4). The reduction of hazard, however, differed in magnitude among patients according to age, liver cirrhosis, diabetes mellitus, and use of metformin. The association was more pronounced in patients younger (adjusted HR, 0.47; 95% CI, 0.30-0.73) versus older than 60 years (adjusted HR, 0.80; 95% CI, 0.59-1.09), without (adjusted HR, 0.56; 95% CI, 0.40-0.80) versus with cirrhosis (adjusted HR, 0.82; 95% CI, 0.56-1.20), and without (adjusted HR, 0.60; 95% CI, 0.45-0.81) versus with diabetes (adjusted HR, 0.86; 95% CI, 0.51-1.44).

thumbnail image

Figure 4. Multivariate stratified analyses for the association between postoperative antiviral therapy and recurrence of hepatocellular carcinoma after resection. All subgroup analyses are adjusted for confounders and accounted for death as the competing cause of risk. CI, confidence interval; HR, hazard ratio; NSAID, nonsteroidal antiinflammatory drug.

Download figure to PowerPoint


  1. Top of page
  2. Abstract
  3. Patients and Methods
  4. Results
  5. Discussion
  6. References

This nationwide population-based study revealed a significantly lower risk of recurrent HCC in CHC patients who were treated for their HCV infection postoperatively with peg-interferon plus ribavirin, as compared with those whose CHC was left untreated. The hazard was reduced by 36% (adjusted HR 0.64; 95% CI, 0.50-0.83; P = 0.001) after adjustment for possible confounding. The unadjusted NNT in association with one patient free of recurrent HCC at 1, 3, and 5 years after antiviral treatment were 12, 8, and 8, respectively. Nevertheless, the magnitude of association appeared to differ among patient subgroups, in that the attenuated risk of HCC recurrence was more apparent in younger patients without cirrhosis or diabetes. These findings not only imply that antiviral treatment may still ameliorate hepatocellular carcinogenesis even when HCV infection has progressed to the stage of HCC, but also characterize those who are more likely to benefit from this management.

To date, there has been no adjuvant therapy approved for HCC after curative resection.6, 7 Conventional interferon alpha has been tested for this indication, but the results from randomized trials involving CHC patients were conflicting.27-30 Kubo et al.27 reported in a small trial (N = 30) that postoperative administration of interferon for 2 years decreased recurrence of resected HCC, whereas Mazzaferro et al.28 concluded that adjuvant interferon for 48 weeks could not prevent HCC recurrence in 150 HCV-infected patients with cirrhosis. The other two randomized trials, which recruited predominantly HBV-infected patients along with some CHC patients, also conflicted in the efficacy for secondary prevention of HCC.29, 30 In addition, the therapeutic agent, dosing protocol, patient characteristic, and study endpoint also varied remarkably across these trials. Therefore, conventional interferon cannot be accepted as the standard care following HCC resection in CHC patients,7 despite a positive result from meta-analyses.31

Peg-interferon alpha plus ribavirin has become the standard anti-HCV regimen for a decade,32, 33 but its efficacy in preventing recurrence of curatively treated HCC remains undetermined. Two previous studies addressing this issue did not find peg-interferon-based therapy was associated with fewer recurrences.34, 35 In a cohort study consisting of 182 patients predominantly receiving radiofrequency ablation, Hagihara et al.34 reported HCC recurred similarly between 37 treated and 145 untreated patients (58% versus 70% at 5 years; P = 0.17). By taking a propensity score approach, Tanimoto et al.35 showed that recurrence did not differ between patients with and without postoperative peg-interferon-based treatment (55.3% versus 44.7%; P = 0.36; n = 38 in both groups). Both studies were probably underpowered because of the small number of participants. Besides, differences in demographics, HCC treatment, antiviral medication, outcome definition, and follow-up duration might also be factors in the discrepancy between their results and ours. Based on our data, it needs a large sample comprising representative subgroups to uncover the association between postoperative antiviral treatment and HCC recurrence, in that the recurrence rate among treated patients may be lower but remain substantial and that certain patient characteristics can modify the association.

Peg-interferon plus ribavirin is highly effective in achieving HCV eradication in Taiwan,36, 37 where a favorable genetic variation in IL28B is prevalent,38 and has been validated among Taiwanese patients with HCC in a multicenter trial.39 However, this study in and of itself could not show how virological response might have influenced the association. Because linking the NHIRD to individual patients' laboratory results was forbidden for privacy protection, we were unable to determine whether viral elimination mediated this association. Nevertheless, a large body of evidence has indicated that sustained virological response to antiviral treatment appears essential to reduce risk of developing HCV-related HCC.15, 16 The large-scale randomized and placebo-controlled HALT-C trial also refuted the antitumor efficacy of peg-interferon in CHC patients who failed to eradicate HCV.40 In our opinion, antiviral efficacy was more likely than an antiproliferative property to account for the observed association in this study, although further research is clearly required to clarify the underlying mechanism. Furthermore, different viral clearance rates could plausibly explain why age, cirrhosis, and diabetes modified the association with recurrent HCC, since these were all validated host features predictive of therapeutic response.41-43 Consistent with our previous study which focused on recurrent HCC in patients with HBV infection,21 this study also uncovered an inverse association between the use of aspirin or NSAID and risk of HCC recurrence. The mechanism of this intriguing finding may involve induction of cell cycle arrest and apoptosis in HCC cells,44, 45 and should inspire more investigation.

This study has applied a number of methodological procedures to avoid a biased or confounded result, in addition to adjusting for multiple parameters in the multivariate analyses. First, enrollment was explicitly restricted to patients who could tolerate and recover from liver resection, whose performance status as well as hepatic reserve was therefore unlikely to contraindicate use of interferon and ribavirin. Second, in order to ensure comparability of the study cohorts, enrolled patients were matched by age, gender, and cirrhosis. The treated and untreated cohorts were consequently similar in their baseline characteristics including the comorbidity index, i.e., the Charlson's score. Moreover, matching in the time period from surgery to administration of antiviral therapy prevented the immortal time bias.23 Third, the universal coverage of Taiwan National Health Insurance, which fully reimbursed peg-interferon and ribavirin for treating HCV infection, precluded healthcare accessibility or financial disparity as a determinant for receiving treatment or not. Last, but not least, we recognized how mortality might have confounded the estimation of the association with HCC recurrence.46 Since antiviral treatment could have affected survival by ameliorating the background liver disease, without relation to any effect on HCC, the higher mortality in the untreated patients would have overestimated their HCC recurrence rate and spuriously exaggerated the difference between the study cohorts, had the censoring caused by death been simply dismissed as noninformative.47, 48 All in all, information from these careful analyses should be valuable for physicians and surgeons who need to weigh the pros and cons of using peg-interferon and ribavirin after resection of HCC, even though the observational nature of this study prevented definite ascertainment of the causal relationship.

Several limitations warrant discussion. First, a lack of direct laboratory results in the Taiwan NHIRD prohibited exploration in terms of virological response, viral genotype, baseline viral load, size and number of tumors, and histological differentiation. Second, we were unable to determine the adverse reactions related to peg-interferon and ribavirin. Nevertheless, nearly 90% of those who ever started postoperative antiviral therapy eventually completed a minimum of a 16-week course, indicating tolerability of this regimen in these patients. Besides, a multicenter trial from Taiwan has confirmed its applicability in HCC patients.39 Finally, for the purpose of internal validity, we deliberately matched the postoperative period prior to antiviral treatment and restricted enrollment in patients free of recurrence within 3 months of surgery. Given that the time pattern of recurrence has been shown to correlate with its pathogenesis,49 recurrent HCC in this study might more likely result from de novo carcinogenesis instead of preexistent micrometastasis. We accordingly suggest caution be exercised before extrapolating our findings in the setting of immediate recurrence following resection.

In summary, recurrence of HCV-related HCC after surgical resection is reduced in patients who receive postoperative antiviral therapy with peg-interferon plus ribavirin, as compared with those who never treat their HCV infection. Moreover, greater risk reduction of recurrent HCC is observed in younger patients (<60 years) and those without cirrhosis or diabetes. These results imply that antiviral therapy appears better late than never in CHC patients with curable HCC. How to improve outcomes when the current therapy is either intolerable or ineffective warrants further research.


  1. Top of page
  2. Abstract
  3. Patients and Methods
  4. Results
  5. Discussion
  6. References
  • 1
    El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004; 127: S27S34.
  • 2
    Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009; 27: 14851491.
  • 3
    El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 25572576.
  • 4
    Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529538.
  • 5
    El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142: 12641273 e1261.
  • 6
    Poon D, Anderson BO, Chen LT, Tanaka K, Lau WY, Van Cutsem E, et al. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 2009; 10: 11111118.
  • 7
    Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. HEPATOLOGY 2011; 53: 10201022.
  • 8
    Yamamoto J, Kosuge T, Takayama T, Shimada K, Yamasaki S, Ozaki H, et al. Recurrence of hepatocellular carcinoma after surgery. Br J Surg 1996; 83: 12191222.
  • 9
    Sasaki Y, Yamada T, Tanaka H, Ohigashi H, Eguchi H, Yano M, et al. Risk of recurrence in a long-term follow-up after surgery in 417 patients with hepatitis B- or hepatitis C-related hepatocellular carcinoma. Ann Surg 2006; 244: 771780.
  • 10
    Ng IO, Guan XY, Poon RT, Fan ST, Lee JM. Determination of the molecular relationship between multiple tumour nodules in hepatocellular carcinoma differentiates multicentric origin from intrahepatic metastasis. J Pathol 2003; 199: 345353.
  • 11
    Morimoto O, Nagano H, Sakon M, Fujiwara Y, Yamada T, Nakagawa H, et al. Diagnosis of intrahepatic metastasis and multicentric carcinogenesis by microsatellite loss of heterozygosity in patients with multiple and recurrent hepatocellular carcinomas. J Hepatol 2003; 39: 215221.
  • 12
    Camma C, Giunta M, Andreone P, Craxi A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 2001; 34: 593602.
  • 13
    Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 15211531.
  • 14
    Lin SM, Yu ML, Lee CM, Chien RN, Sheen IS, Chu CM, et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 2007; 46: 4552.
  • 15
    Yu ML, Lin SM, Chuang WL, Dai CY, Wang JH, Lu SN, et al. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antivir Ther 2006; 11: 985994.
  • 16
    Singal AK, Singh A, Jaganmohan S, Guturu P, Mummadi R, Kuo YF, et al. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 2010; 8: 192199.
  • 17
    Makiyama A, Itoh Y, Kasahara A, Imai Y, Kawata S, Yoshioka K, et al. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. Cancer 2004; 101: 16161622.
  • 18
    Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. HEPATOLOGY 2009; 49: 13351374.
  • 19
    Wu CY, Wu MS, Kuo KN, Wang CB, Chen YJ, Lin JT. Effective reduction of gastric cancer risk with regular use of nonsteroidal anti-inflammatory drugs in Helicobacter pylori-infected patients. J Clin Oncol 2010; 28: 29522957.
  • 20
    Chen HP, Shieh JJ, Chang CC, Chen TT, Lin JT, Wu MS, et al. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut 2012 [Epub ahead of print].
  • 21
    Wu CY, Chen YJ, Ho JH, Hsu YC, Kuo KN, Wu MS, et al. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma following liver resection. JAMA 2012; 308: 19061914.
  • 22
    Pittet D, Tarara D, Wenzel RP. Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1994; 271: 15981601.
  • 23
    Shariff SZ, Cuerden MS, Jain AK, Garg AX. The secret of immortal time bias in epidemiologic studies. J Am Soc Nephrol 2008; 19: 841843.
  • 24
    Simons JP, Ng SC, Hill JS, Shah SA, Zhou Z, Tseng JF. In-hospital mortality from liver resection for hepatocellular carcinoma: a simple risk score. Cancer 2010; 116: 17331738.
  • 25
    Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 11411154.
  • 26
    Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. JASA 1999; 94: 496509.
  • 27
    Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Yamazaki O, et al. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med 2001; 134: 963967.
  • 28
    Mazzaferro V, Romito R, Schiavo M, Mariani L, Camerini T, Bhoori S, et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. HEPATOLOGY 2006; 44: 15431554.
  • 29
    Lo CM, Liu CL, Chan SC, Lam CM, Poon RT, Ng IO, et al. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg 2007; 245: 831842.
  • 30
    Chen LT, Chen MF, Li LA, Lee PH, Jeng LB, Lin DY, et al. Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection. Ann Surg 2012; 255: 817.
  • 31
    Miyake Y, Takaki A, Iwasaki Y, Yamamoto K. Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. J Viral Hepat 2010; 17: 287292.
  • 32
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958965.
  • 33
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975982.
  • 34
    Hagihara H, Nouso K, Kobayashi Y, Iwasaki Y, Nakamura S, Kuwaki K, et al. Effect of pegylated interferon therapy on intrahepatic recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. Int J Clin Oncol 2011; 16: 210220.
  • 35
    Tanimoto Y, Tashiro H, Aikata H, Amano H, Oshita A, Kobayashi T, et al. Impact of pegylated interferon therapy on outcomes of patients with hepatitis C virus-related hepatocellular carcinoma after curative hepatic resection. Ann Surg Oncol 2012; 19: 418425.
  • 36
    Yu ML, Dai CY, Huang JF, Hou NJ, Lee LP, Hsieh MY, et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007; 56: 553559.
  • 37
    Liu CH, Liu CJ, Lin CL, Liang CC, Hsu SJ, Yang SS, et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis 2008; 47: 12601269.
  • 38
    Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399401.
  • 39
    Huang JF, Yu ML, Huang CF, Chiu CF, Dai CY, Huang CI, et al. The efficacy and safety of pegylated interferon plus ribavirin combination therapy in chronic hepatitis C patients with hepatocellular carcinoma post curative therapies — a multicenter prospective trial. J Hepatol 2011; 54: 219226.
  • 40
    Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, et al. Prolonged therapy of advanced hepatitis C with low-dose peginterferon. N Engl J Med 2008; 359: 24292441
  • 41
    Hadziyannis SJ, Sette HJr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346355.
  • 42
    Huang CF, Yang JF, Dai CY, Huang JF, Hou NJ, Hsieh MY, et al. Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C. J Infect Dis 2010; 201: 751759.
  • 43
    Romero-Gomez M, Del Mar Viloria M, Andrade RJ, Salmeron J, Diago M, Fernandez-Rodriguez CM, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128: 636641.
  • 44
    Raza H, John A, Benedict S. Acetylsalicylic acid induced oxidative stress, cell cycle arrest, apoptosis and mitochondrial dysfunction in human hepatoma HepG2 cells. Eur J Pharmacol 2011; 668: 1524.
  • 45
    Hossain MA, Kim DH, Jang JY, Kang YJ, Yoon JH, Moon JO, et al. Aspirin induces apoptosis in vitro and inhibits tumor growth of human hepatocellular carcinoma cells in a nude mouse xenograft model. Int J Oncol 2012; 40: 12981304.
  • 46
    Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698711.
  • 47
    Satagopan JM, Ben-Porat L, Berwick M, Robson M, Kutler D, Auerbach AD. A note on competing risks in survival data analysis. Br J Cancer 2004; 91: 12291235.
  • 48
    Hsu YC, Lin JT, Chen TT, Wu MS, Wu CY. Long-term risk of recurrent peptic ulcer bleeding in patients with liver cirrhosis: a 10-year nationwide cohort study. HEPATOLOGY 2012; 56: 698705.
  • 49
    Wu JC, Huang YH, Chau GY, Su CW, Lai CR, Lee PC, et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol 2009; 51: 890897.